ClinicalTrials.gg
CompletedNCT02966353REALISEUpdated Apr 30, 2020Results posted

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

A Phase 2 interventional study of ruxolitinib in Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
19th of 50
51 · median 45
Started
2017
with 1 other
Phase 2
19 of 50
3 open now
Registered
31st of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 19th largest by enrollment, is one of 2 that started in 2017, is one of 19 in phase 2, and was the 31st registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This was a study of treatment with ruxolitinib in patients who presented with transfusion dependent or independent anemia. Starting dose was 10 mg BID. This dose was maintained for the first 12 weeks of the study and up-titrated thereafter unless the subject met criteria for dose hold or dose reduction

Read the detailed description

This was a study of treatment with ruxolitinib in patients who present with transfusion dependent or independent anemia at screening defined as an hemoglobin \<10 g/dL with 10 mg BID starting dose with subsequent up titrations (maximum dose 25 mg BID) depending on safety and efficacy. This dosing approach for anemic MF patients will be systematically studied in this prospective multicenter phase II open label single arm trial to determine if the levels of spleen length reduction and symptom improvement are consistent with those reported in previous clinical trials with ruxolitinib in patients with anemia and doses according to platelet counts at the moment of treatment initiation, and whether this lower starting dose and up titration approach may minimize the initial hemoglobin and platelet declines and transfusion requirements.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-Polycythemia Vera-Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis

Keywords

  • Ruxolitinib
  • anemia
  • Primary Myelofibrosis
  • PMF
  • Post-Polycythemia Vera-Myelofibrosis
  • PPV-MF
  • Post-Essential Thrombocythemia Myelofibrosis
  • PET-MF
  • adult
  • INC424
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Written must be obtained prior to any screening procedures.

  1. Male or female patients aged ≥ 18 years of age.
  2. Patients must have been diagnosed with PMF, according to the 2016 revised International Standard Criteria, PPV MF or PET-MF, irrespective of JAK2 mutation status.
  3. Patients must have had palpable splenomegaly that is equal to or greater than 5 cm below the left costal margin.
  4. Patients must have had less than 10 g/dL
  5. Patients must have had a history of transfusions must have a documented transfusion record in the previous 12 weeks to baseline.
  6. Patients must have had performance status of 0, 1, or 2.
  7. Patients must have had a peripheral blood blast percentage count of \< 10%.
  8. Patients must have recovered or stabilized sufficiently from any adverse drug reactions associated with prior treatments before beginning treatment with ruxolitinib.

Exclusion criteria

Exclusion Criteria:

  1. Patients who had prior treatment with any JAK1 or JAK2 inhibitor.
  2. Patients who had known to ruxolitinib or other JAK1/JAK2 inhibitors, or to their .
  3. Patients who had been eligible for hematopoietic stem cell transplantation (suitable candidate and a suitable donor is available).
  4. Patients who had inadequate bone marrow reserve at baseline as demonstrated by at least one of the following:

    1. ANC that is ≤ 1,000/µL.
    2. count that is \<50,000/µL without the assistance of growth factors, thrombopoietic factors or platelet transfusions.
    3. count that is ≤ 6.5 g/dL despite transfusions.
  5. Patients who had severely impaired renal function defined by: less than 30 mL/min.
  6. Patients who had inadequate liver function defined by any of these:

    1. Total ≥ 2.5 x and subsequent determination of direct bilirubin ≥ 2.5 x ULN;
    2. (ALT) > 2.5 x ULN;
    3. Aspartate aminotransferase (AST) > 2.5 x ULN.
  7. Patients who were being treated concurrently with a strong (potent) systemic inhibitor or inducer of at the time of Screening.
  8. Presence of active bacterial, fungal, parasitic, or viral infection which requires therapy.
  9. Known history of (HIV) infection or other immunodeficiency syndromes such as X-linked agammaglobulinemia and common variable immune deficiency.
  10. Acute viral hepatitis or active chronic or C infection. Patients with inactive chronic infection (without viral replication) can be enrolled
  11. History of progressive multifocal leuko-encephalopathy.
  12. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ruxolitinib .
  13. History or current diagnosis of uncontrolled or significant cardiac disease, including any of the following:

    1. Myocardial infarction within last 6 months
    2. Uncontrolled congestive heart failure
    3. Unstable angina within last 6 months
    4. (symptomatic) cardiac arrhythmias (e.g. bradyarrhythmias, sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker)
  14. Significant concurrent, uncontrolled medical condition which, in the investigator's opinion, would have jeopardized the safety of the patient or compliance with the protocol.
  15. Patients who were undergoing treatment with another medication or had been treated with an investigational medication within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
  16. Patients who had a history of in the past 3 years, except for treated early stage squamous or basal cell carcinoma.
  17. Patients who were unable to comprehend or are unwilling to sign an ICF.
  18. Pregnant or nursing (lactating) women
  19. Women of , defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of throughout the study duration inclusive of 30 day safety follow up.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    All Subjects

    10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.

    Drug: ruxolitinib

Interventions

  • Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 24

    Percentage of participants achieving a 50% reduction in spleen length at week 24. For subjects with palpable spleen at baseline and non-palpable at post-baseline, the post-baseline spleen are imputed as 0. Subjects who had palpable, but missing spleen length at baseline is excluded from the analysis. Subjects with missing spleen length at Week 24 or who withdraw earlier from the study are considered as a non-responder. The 95% CI is computed using exact Clopper-Pearson method.

    Time frame: Baseline up to week 24

Secondary outcomes

  1. Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 48

    Percentage of participants achieving a 50% reduction in spleen length at week 48. For subjects with palpable spleen at baseline and non-palpable at post-baseline, the post-baseline spleen is imputed as 0. Subjects who had palpable, but missing spleen length at baseline is excluded from the analysis. Subjects with missing spleen length at Week 48 or who withdraw earlier from the study are considered as a non-responder. The 95% CI is computed using exact Clopper-Pearson method.

    Time frame: Baseline up to week 48

  2. Percentage of Participants by Spleen Length Reduction or no Increase From Baseline Category at Week 24 and Week 48

    Participants who achieved a ≤ 50% reduction in spleen length at week 24 and 48 (reduction) and participants who had no increase greater than or equal to 50% (increase). The edge of the spleen shall be determined by palpation, measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion. For subjects with palpable spleen at baseline and non-palpable at post-baseline, the post-baseline spleen is imputed as 0.

    Time frame: baseline, weeks 24 and 48

  3. Percentage of Participants With at Least a 50% Reduction in Myelofibrosis 7 Item Symptom Scale (MF-7) and Myelofibrosis Symptom Assessment Form (MFSAF) at Week 24

    The MF-7 is a disease specific questionnaire comprised of 7 items that measures the severity of seven of the most prevalent associated symptoms including: tiredness, early satiety, abdominal discomfort, night sweats, itching (pruritus), bone pain (diffuse not joint or arthritis) and pain under ribs on left side. Each item was scored on a scale ranging from 0 (absent) to 10 (worst imaginable). The MF-7 score is computed as the sum of the observed scores in the individual items to achieve a 0 to 70 score. There would be one recall period of 24 hours used in this questionnaire. A separate question on Inactivity was to be measured for severity of this symptom on a scale from 0 (absent) to 10 (worst imaginable). This would allow the computation of the MFSAF v2.0 questionnaire results, as 6 out of 7 items in the latter PRO are in overlap with MF7 (they also share same 0-10 range Likert scale and ascending order, absent to worst imaginable).

    Time frame: Baseline and week 24

  4. Patient Global Impression of Change (PGIC) at Week 24 and Week 48

    The PGIC is comprised of a single question intended to measure a subject's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where '1' equals very much improved and '7' equals very much worse.

    Time frame: Baseline up to week 48

  5. Percentage of Participants Transfusion Independency From Baseline up to Week 96

    Percentage is based on number of subjects who are transfusion dependent at baseline. Transfusion dependence (TD) is defined as subjects receiving 6 or more units of transfusions 12 weeks prior to baseline. Transfusion independence (TI) rate is defined as subjects who are transfusion dependent at baseline and require no unit of transfusion for ≥ 12 weeks at any time during the study. Transfusion response rate is defined as subjects who are TD at baseline and have 5 or less units of transfusion for ≥ 12 weeks at any time during the study.

    Time frame: Baseline up to week 96

07

Results

Posted Apr 30, 2020

Participant flow

Participant flow — Overall Study
MilestoneAll Subjects
Started51
Completed after data cutoff1
Completed29
Not completed22
Withdrew: Withdrawal by subject7
Withdrew: Adverse event4
Withdrew: Death4
Withdrew: Physician decision3
Withdrew: Progressive disease2
Withdrew: Protocol deviation2

Outcome measures

PrimaryPercentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 24

Percentage of participants achieving a 50% reduction in spleen length at week 24. For subjects with palpable spleen at baseline and non-palpable at post-baseline, the post-baseline spleen are imputed as 0. Subjects who had palpable, but missing spleen length at baseline is excluded from the analysis. Subjects with missing spleen length at Week 24 or who withdraw earlier from the study are considered as a non-responder. The 95% CI is computed using exact Clopper-Pearson method.

Time frame:
Baseline up to week 24
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 24
percentage of participantsAll Subjects
Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 2456.0 (41.3 to 70.0)
SecondaryPercentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 48

Percentage of participants achieving a 50% reduction in spleen length at week 48. For subjects with palpable spleen at baseline and non-palpable at post-baseline, the post-baseline spleen is imputed as 0. Subjects who had palpable, but missing spleen length at baseline is excluded from the analysis. Subjects with missing spleen length at Week 48 or who withdraw earlier from the study are considered as a non-responder. The 95% CI is computed using exact Clopper-Pearson method.

Time frame:
Baseline up to week 48
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 48
percentage of participantsAll Subjects
Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 4836.0 (22.9 to 50.8)
SecondaryPercentage of Participants by Spleen Length Reduction or no Increase From Baseline Category at Week 24 and Week 48

Participants who achieved a ≤ 50% reduction in spleen length at week 24 and 48 (reduction) and participants who had no increase greater than or equal to 50% (increase). The edge of the spleen shall be determined by palpation, measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion. For subjects with palpable spleen at baseline and non-palpable at post-baseline, the post-baseline spleen is imputed as 0.

Time frame:
baseline, weeks 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants by Spleen Length Reduction or no Increase From Baseline Category at Week 24 and Week 48
percentage of participantsAll Subjects
Wk 24 ≤ -50% reduction n=4365.1
Wk 24 -50%, -25% reduction n=4311.6
Wk 24 -25%, -5% reduction n=439.3
Wk 24 -5%, 5% reduction, increase n=434.7
Wk 24 5%, 25% increase n=439.3
Wk 24 25%, 50% increase n=430
Wk 24 >50% increase n=430
Wk 24 remained non-palpable n=430
Wk 24 became palpable n=430
Wk 48 ≤ -50% reduction n=3650.0
Wk 48 -50%, -25% reduction n=3622.2
Wk 48 -25%, -5% reduction n=3616.7
Wk 48 -5%, 5% reduction, increase n=365.6
Wk 48 5%, 25% increase n=362.8
Wk 48 25%, 50% increase n=362.8
Wk 48 >50% increase n=360
Wk 48 remained non-palpable n=360
Wk 48 became palpable n=360
SecondaryPercentage of Participants With at Least a 50% Reduction in Myelofibrosis 7 Item Symptom Scale (MF-7) and Myelofibrosis Symptom Assessment Form (MFSAF) at Week 24

The MF-7 is a disease specific questionnaire comprised of 7 items that measures the severity of seven of the most prevalent associated symptoms including: tiredness, early satiety, abdominal discomfort, night sweats, itching (pruritus), bone pain (diffuse not joint or arthritis) and pain under ribs on left side. Each item was scored on a scale ranging from 0 (absent) to 10 (worst imaginable). The MF-7 score is computed as the sum of the observed scores in the individual items to achieve a 0 to 70 score. There would be one recall period of 24 hours used in this questionnaire. A separate question on Inactivity was to be measured for severity of this symptom on a scale from 0 (absent) to 10 (worst imaginable). This would allow the computation of the MFSAF v2.0 questionnaire results, as 6 out of 7 items in the latter PRO are in overlap with MF7 (they also share same 0-10 range Likert scale and ascending order, absent to worst imaginable).

Time frame:
Baseline and week 24
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 50% Reduction in Myelofibrosis 7 Item Symptom Scale (MF-7) and Myelofibrosis Symptom Assessment Form (MFSAF) at Week 24
percentage of participantsAll Subjects
MF-7 Total Symptom score51.1 (35.8 to 66.3)
Modified MFSAF v2.0 Total symptom score55.6 (40.0 to 70.4)
SecondaryPatient Global Impression of Change (PGIC) at Week 24 and Week 48

The PGIC is comprised of a single question intended to measure a subject's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where '1' equals very much improved and '7' equals very much worse.

Time frame:
Baseline up to week 48
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) at Week 24 and Week 48
ParticipantsAll Subjects
Week 24 n=41 Very much improved5
Week 24 n=41 Much improved20
Week 24 n=41 Minimally improved9
Week 24 n=41 No change6
Week 24 n=41 Minimally worse1
Week 24 n=41 Much worse0
Week 24 n=41 Very much worse0
Week 48 n=33 Very much improved5
Week 48 n=33 Much improved15
Week 48 n=33 Minimally improved9
Week 48 n=33 No change4
Week 48 n=33 Minimally worse0
Week 48 n=33 Much worse0
Week 48 n=33 Very much worse0
SecondaryPercentage of Participants Transfusion Independency From Baseline up to Week 96

Percentage is based on number of subjects who are transfusion dependent at baseline. Transfusion dependence (TD) is defined as subjects receiving 6 or more units of transfusions 12 weeks prior to baseline. Transfusion independence (TI) rate is defined as subjects who are transfusion dependent at baseline and require no unit of transfusion for ≥ 12 weeks at any time during the study. Transfusion response rate is defined as subjects who are TD at baseline and have 5 or less units of transfusion for ≥ 12 weeks at any time during the study.

Time frame:
Baseline up to week 96
Reported as:
Number · percentage of participants
Percentage of Participants Transfusion Independency From Baseline up to Week 96
percentage of participantsAll Subjects
Week 24 transfusion independent rate0
Week 24 transfusion responder rate44.4
Week 48 transfusion independent rate0
Week 48 transfusion responder rate66.7
Week 72 transfusion independent rate0
Week 72 transfusion responder rate66.7
Week 96 transfusion independent rate0
Week 96 transfusion responder rate66.7

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 100 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Patients7/51 (13.7%)17/51 (33.3%)40/51 (78.4%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAll Patients
AnaemiaBlood and lymphatic system disorders3/51
Cardiac failureCardiac disorders2/51
PneumoniaInfections and infestations2/51
Haemolytic anaemiaBlood and lymphatic system disorders1/51
PancytopeniaBlood and lymphatic system disorders1/51
ThrombocytopeniaBlood and lymphatic system disorders1/51
Aortic valve diseaseCardiac disorders1/51
Atrial fibrillationCardiac disorders1/51
Cardiac failure acuteCardiac disorders1/51
Myocardial ischaemiaCardiac disorders1/51
Most frequent other events
Showing 10 of 27
Most frequent other events
EventAll Patients
AnaemiaBlood and lymphatic system disorders17/51
ThrombocytopeniaBlood and lymphatic system disorders14/51
DiarrhoeaGastrointestinal disorders6/51
AstheniaGeneral disorders6/51
Gamma-glutamyltransferase increasedInvestigations6/51
FatigueGeneral disorders5/51
Urinary tract infectionInfections and infestations5/51
Alanine aminotransferase increasedInvestigations5/51
Aspartate aminotransferase increasedInvestigations5/51
PyrexiaGeneral disorders4/51

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Subjects
<=18 years0
Between 18 and 65 years20
>=65 years31
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female21
Male30
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Subjects
White48
Asian3
Type of myelofibrosis
Type of myelofibrosis(participants)All Subjects
Primary myelofibrosis34
Post-polycythemia vera myelofibrosis6
Post-essential thrombocythemia myelofibrosis11
Time since intial diagnosis
Time since intial diagnosis(months)All Subjects
Mean32.9 ± 44.16
Bone Marrow Fibrosis Grade at Diagnosis
Bone Marrow Fibrosis Grade at Diagnosis(participants)All Subjects
Grade 00
Grade 16
Grade 226
Grade 318
Missing1
Constitutional symptoms
Constitutional symptoms(participants)All Subjects
Present29
Absent22
Palpable spleen length (cm) below costal margin
Palpable spleen length (cm) below costal margin(centimeters)All Subjects
Mean11.7 ± 6.20

2 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Novartis Investigative Site
    Vienna, A-1090, Austria
  • Novartis Investigative Site
    Antwerpen, 2060, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Sofia, 1413, Bulgaria
  • Novartis Investigative Site
    Sofia, 1756, Bulgaria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Halle S, 06120, Germany
  • Novartis Investigative Site
    Athens, GR 115 27, Greece
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113-8431, Japan
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
  • Novartis Investigative Site
    Moscow, 129110, Russian Federation
  • Novartis Investigative Site
    Petrozavodsk, 185019, Russian Federation
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jul 2018, 15 months.

Results were first posted in Apr 2020, 1 year 9 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 15 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2016
First posted
Nov 17, 2016
StartActual
Mar 31, 2017
Primary completionActual
Jul 24, 2018
CompletionActual
Feb 15, 2019
Results first posted
Apr 30, 2020
Last update
Apr 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02966353
Responsible party
Sponsor
First posted
Nov 17, 2016
Start date
Mar 31, 2017
Primary completion
Jul 24, 2018
Completion
Feb 15, 2019
Results posted
Apr 30, 2020
Last update
Apr 30, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion